We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
Read MoreHide Full Article
Acadia Pharmaceuticals Inc. (ACAD - Free Report) shares lost 15% in the after-market hours on Mar 11, after the company announced the failure of its late-stage study evaluating pimavanserin for the treatment of negative symptoms of schizophrenia.
In the phase III ADVANCE-2 study, treatment with pimavanserin did not achieve statistical significance in demonstrating improvement over placebo on the study’s primary endpoint of change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score. The NSA-16 scale is a widely used metric to measure change in the wide range of predominant negative symptoms that patients experience.
Based on such disappointing results, Acadia has decided not to pursue any further clinical studies with pimavanserin. However, the company will continue to analyze data from the schizophrenia study of pimavanserin.
Pimavanserin was, however, well-tolerated in the ADVANCE-2 study and had a safety profile consistent with previous clinical studies. Adverse events related to treatment with the drug were minimal.
In the past year, shares of Acadia have gained 24.3% against the industry’s 4.6% decline.
Image Source: Zacks Investment Research
Notably, ACAD is not new to developmental/regulatory setbacks for pimavanserin. The company had previously failed to gain label expansion for pimavanserin to treat hallucinations and delusions associated with dementia-related psychosis and Alzheimer’s disease psychosis (ADP) in 2021 and 2022, respectively.
We remind the investors that Acadia’s pimavanserin is currently marketed in the United States as the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis. The drug was launched in May 2016 under the brand name Nuplazid.
Nuplazid recorded sales worth $549.2 million in 2023, up 6% year over year. Total Nuplazid sales accounted for about 76% of the company’s revenues in 2023.
Despite the significant setback leading to the abandonment of further clinical studies with pimavanserin, Acadia’s pipeline beyond Nuplazid is reassuring.
The company is currently evaluating the efficacy and safety of carbetocin nasal spray (ACP-101) in a phase III COMPASS study for treating hyperphagia associated with Prader-Willi Syndrome.
The company is also developing ACP-204 as a potential treatment for ADP. ACAD completed phase I development of ACP-204, witnessing a favorable safety and tolerability profile. In the fourth quarter of 2023, Acadia announced that it has initiated a mid-stage study to evaluate the safety and efficacy of ACP-204 to treat hallucinations and delusions associated with ADP.
The phase II study, initiated by the company, is the first part of the planned phase II/III clinical program for ACP-204 in the treatment of ADP. The mid-late-stage program comprises a single phase II study and two phase III studies that have almost identical designs.
In the past 30 days, the Zacks Consensus Estimate for ADMA Biologics’ 2024 earnings per share (EPS) has increased from 22 cents to 30 cents. During the same period, the estimate for ADMA’s 2025 EPS has increased from 32 cents to 50 cents. Over the past year, shares of ADMA have surged 94.3%.
ADMA beat estimates in three of the trailing four quarters and matched in one, delivering an average earnings surprise of 85%.
In the past 30 days, the Zacks Consensus Estimate for FibroGen’s 2024 loss per share has narrowed from $1.14 to $1.09. During the same period, the estimate for FibroGen’s 2025 loss per share is pegged at 6 cents. Over the past year, shares of the FGEN have plunged 91.5%.
FGEN beat estimates in two of the trailing four quarters, missing the mark on the other two occasions, delivering an average negative surprise of 2.26%.
In the past 30 days, the Zacks Consensus Estimate for Adicet Bio’s 2023 loss per share has remained constant at $3.39. During the same period, the consensus estimate for Adicet’s 2024 loss per share has widened from $1.80 to $1.81. In the past year, shares of ACET have plunged 68.2%.
ACET beat estimates in two of the trailing four quarters, missing the mark on the other two occasions, delivering an average negative surprise of 8.36%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
Acadia Pharmaceuticals Inc. (ACAD - Free Report) shares lost 15% in the after-market hours on Mar 11, after the company announced the failure of its late-stage study evaluating pimavanserin for the treatment of negative symptoms of schizophrenia.
In the phase III ADVANCE-2 study, treatment with pimavanserin did not achieve statistical significance in demonstrating improvement over placebo on the study’s primary endpoint of change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score. The NSA-16 scale is a widely used metric to measure change in the wide range of predominant negative symptoms that patients experience.
Based on such disappointing results, Acadia has decided not to pursue any further clinical studies with pimavanserin. However, the company will continue to analyze data from the schizophrenia study of pimavanserin.
Pimavanserin was, however, well-tolerated in the ADVANCE-2 study and had a safety profile consistent with previous clinical studies. Adverse events related to treatment with the drug were minimal.
In the past year, shares of Acadia have gained 24.3% against the industry’s 4.6% decline.
Image Source: Zacks Investment Research
Notably, ACAD is not new to developmental/regulatory setbacks for pimavanserin. The company had previously failed to gain label expansion for pimavanserin to treat hallucinations and delusions associated with dementia-related psychosis and Alzheimer’s disease psychosis (ADP) in 2021 and 2022, respectively.
We remind the investors that Acadia’s pimavanserin is currently marketed in the United States as the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis. The drug was launched in May 2016 under the brand name Nuplazid.
Nuplazid recorded sales worth $549.2 million in 2023, up 6% year over year. Total Nuplazid sales accounted for about 76% of the company’s revenues in 2023.
Despite the significant setback leading to the abandonment of further clinical studies with pimavanserin, Acadia’s pipeline beyond Nuplazid is reassuring.
The company is currently evaluating the efficacy and safety of carbetocin nasal spray (ACP-101) in a phase III COMPASS study for treating hyperphagia associated with Prader-Willi Syndrome.
The company is also developing ACP-204 as a potential treatment for ADP. ACAD completed phase I development of ACP-204, witnessing a favorable safety and tolerability profile. In the fourth quarter of 2023, Acadia announced that it has initiated a mid-stage study to evaluate the safety and efficacy of ACP-204 to treat hallucinations and delusions associated with ADP.
The phase II study, initiated by the company, is the first part of the planned phase II/III clinical program for ACP-204 in the treatment of ADP. The mid-late-stage program comprises a single phase II study and two phase III studies that have almost identical designs.
ACADIA Pharmaceuticals Inc. Price and Consensus
ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote
Zacks Rank and Stocks to Consider
Acadia currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the drug/biotech industry are ADMA Biologics (ADMA - Free Report) , FibroGen (FGEN - Free Report) and Adicet Bio, Inc. (ACET - Free Report) . While ADMA sports a Zacks Rank #1 (Strong Buy), FGEN and ACET carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, the Zacks Consensus Estimate for ADMA Biologics’ 2024 earnings per share (EPS) has increased from 22 cents to 30 cents. During the same period, the estimate for ADMA’s 2025 EPS has increased from 32 cents to 50 cents. Over the past year, shares of ADMA have surged 94.3%.
ADMA beat estimates in three of the trailing four quarters and matched in one, delivering an average earnings surprise of 85%.
In the past 30 days, the Zacks Consensus Estimate for FibroGen’s 2024 loss per share has narrowed from $1.14 to $1.09. During the same period, the estimate for FibroGen’s 2025 loss per share is pegged at 6 cents. Over the past year, shares of the FGEN have plunged 91.5%.
FGEN beat estimates in two of the trailing four quarters, missing the mark on the other two occasions, delivering an average negative surprise of 2.26%.
In the past 30 days, the Zacks Consensus Estimate for Adicet Bio’s 2023 loss per share has remained constant at $3.39. During the same period, the consensus estimate for Adicet’s 2024 loss per share has widened from $1.80 to $1.81. In the past year, shares of ACET have plunged 68.2%.
ACET beat estimates in two of the trailing four quarters, missing the mark on the other two occasions, delivering an average negative surprise of 8.36%.